PCAC Results 2026: 6 Peptides Cleared for Compounding, 1 Rejected
The FDA advisory committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the 503A Bulks List. Emideltide was the lone rejection. Here's the full scorecard, what every vote means, and the rulemaking road ahead.
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee convened at the White Oak Campus in Silver Spring, Maryland, to review seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List. Across two days of testimony, debate, and voting, the 14-member panel recommended six and rejected one — overriding FDA staff scientists who had recommended against listing all seven.
That last detail matters. The committee broke from the agency’s own position on every substance except emideltide. Observers in the room described an audible reaction when the first tally was read. It was, by several accounts, a historically unusual outcome for a PCAC panel.
But here’s what most of the coverage has gotten wrong: none of these peptides became legal to compound on the spot. The votes are advisory. They do not change legal status. They begin a rulemaking process that is likely to stretch well into 2027.
Three separate legal events keep getting collapsed into one headline, and understanding the difference between them is the entire point of this article.
The Complete Scorecard
| Peptide | Day | Vote | Result | Reviewed For |
|---|---|---|---|---|
| BPC-157 | 1 | 8-6-1 | Recommended | Ulcerative colitis, tissue repair |
| KPV | 1 | 8-6-1 | Recommended | Wound healing, inflammatory conditions |
| TB-500 | 1 | 8-6-1 | Recommended | Wound healing |
| MOTS-c | 1 | 7-5-2 | Recommended | Obesity, osteoporosis |
| Epitalon | 2 | 7-4-1 | Recommended | Longevity, telomere support |
| Semax | 2 | 8-5-1 | Recommended | Neurologic uses |
| Emideltide (DSIP) | 2 | 6-7-1 | Rejected | Insomnia |
Vote format is Yes-No-Abstain. Both free-base and acetate salt forms were reviewed for each peptide; in every case, both forms received the same result. The FDA had recommended against inclusion for all seven.
Three Legal Events That Keep Getting Confused
Since early 2026, three distinct regulatory developments have affected these peptides. They are related but independent, and conflating them leads to bad decisions about sourcing, legality, and timing.
1. Category 2 Removal — April 23, 2026
HHS Secretary Kennedy confirmed the removal of 12 peptides from Category 2, the FDA’s list of substances that “may not be compounded.” BPC-157, TB-500, MOTS-c, GHK-Cu (injectable), Melanotan II, Semax, and PEG-MGF were among them. This removed the explicit prohibition but did not create an affirmative legal pathway for compounding. Coming off Category 2 is not the same thing as being cleared to compound.
2. PCAC Recommendation — July 23–24, 2026
This is the event covered in this article. The advisory committee recommended six peptides for the 503A Bulks List. These votes are non-binding expert advice to the FDA. They carry weight in the rulemaking record but do not have the force of law on their own.
3. Formal 503A Bulks List Placement — Pending
This is the step that would actually authorize compounding. It requires the FDA to publish a Notice of Proposed Rulemaking (NPRM), open a public comment period, and issue a final rule. Based on historical timelines, this process typically takes 12 to 24 months from the advisory vote. Realistic expectations point to sometime in 2027.
A PCAC recommendation is not FDA approval. These peptides have not been through clinical trials. They have not received new drug applications. The 503A pathway authorizes compounding pharmacies to prepare a substance — it does not make the substance an “approved drug” in any regulatory sense. That distinction matters for insurance coverage, provider liability, and patient expectations.
What Happened on Day 1: BPC-157, KPV, TB-500, MOTS-c
The first day reviewed four peptides, and all four received favorable recommendations despite the FDA review staff’s written position against listing any of them.
BPC-157 was the headline event. It is the most widely searched peptide in the compounding space, with over 300 published preclinical papers documenting its profile in tissue repair, gut healing, and tendon recovery. The original nomination by LDT Health Solutions on behalf of the International Peptide Society had been withdrawn, but the FDA elected to proceed with the review anyway. The committee voted 8-6 with one abstention, directly overriding staff’s recommendation. The reviewed use was ulcerative colitis, though the preclinical literature spans far more broadly. Read our full BPC-157 profile for the research breakdown.
KPV, an alpha-melanocyte-stimulating hormone fragment studied for anti-inflammatory and wound-healing applications, received the same 8-6-1 tally. Like BPC-157, its original nomination had been withdrawn but the FDA chose to proceed. KPV’s research profile is smaller than BPC-157’s, but the committee found sufficient basis to recommend it for wound healing and inflammatory conditions. See our KPV deep dive.
TB-500, a synthetic analog of thymosin beta-4 studied for wound healing and tissue repair, also passed 8-6-1. TB-500 is frequently discussed alongside BPC-157 in recovery protocols. Its preclinical profile covers cardiac, dermal, and musculoskeletal repair pathways.
MOTS-c, a mitochondrial-derived peptide evaluated for obesity and osteoporosis, passed with a slightly narrower margin: 7-5 with two abstentions. MOTS-c is notable as a naturally occurring peptide encoded by mitochondrial DNA, which committee members found relevant to the safety characterization discussion. Explore the full MOTS-c research profile.
What Happened on Day 2: Epitalon, Semax, Emideltide
Epitalon, a synthetic tetrapeptide studied for its role in telomere biology and longevity, passed 7-4 with one abstention. The longevity and anti-aging research community has followed epitalon closely, and its inclusion on the recommended list was viewed as a signal that the committee was receptive to the emerging longevity medicine category. Read our Epitalon profile.
Semax, a synthetic heptapeptide analog of ACTH(4-10) studied for neurologic applications including cognitive enhancement and neuroprotection, passed 8-5 with one abstention. Semax has an extensive clinical history in Russia, where it has been used as a prescription medication. The committee found sufficient basis in its safety and characterization data to recommend it. See the full Semax research overview.
Emideltide (DSIP) was the only rejection, voted down 6-7 with one abstention. The panel cited several concerns: weak efficacy evidence for its proposed use in insomnia, poor chemical characterization, the existence of FDA-approved alternatives for sleep disorders, and the fact that the nominator had withdrawn the submission — the FDA was reviewing it at its own election. This was the one instance where the committee aligned with FDA staff.
What the Category 1 Framework Means Right Now
While the formal rulemaking process plays out, these peptides exist in an intermediate legal space under the FDA’s Category 1 interim enforcement policy. Category 1 means the FDA does not intend to take enforcement action against licensed 503A compounding pharmacies that prepare the substance for individual patients with a valid prescription.
This is not the same as being on the 503A Bulks List. The Bulks List is codified at 21 C.F.R. § 216.23. Category 1 is an enforcement posture. The practical difference: a provider and pharmacy operating under Category 1 carry more regulatory uncertainty than they would under a formal listing, but the FDA has signaled it will not pursue action against compliant operators.
Some telehealth providers and clinics are currently prescribing these peptides under this framework. If you’re considering that route, our guide on how to get peptides prescribed covers the process, including what bloodwork to expect and how to find a licensed provider.
The Rulemaking Road Ahead
These timelines are estimates based on historical rulemaking speed. The FDA is not bound to follow the committee’s recommendation, though departing from a favorable advisory vote without explanation would be procedurally unusual. The involvement of HHS Secretary Kennedy, who has been publicly supportive of expanding peptide access, is also a factor — NCPA reporting noted that Kennedy will need to formally approve additions to the list.
The July meeting covered only seven of the peptides being considered. Five additional peptides are scheduled for a second PCAC meeting before February 2027. The specific substances and dates have not yet been announced. We’ll cover that meeting as the details become available.
The Separate GLP-1 Story: 503B Exclusion
Running parallel to the peptide compounding expansion is a contraction on the GLP-1 side. On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period, extended once, closed on July 30, 2026. A final rule is expected in the coming months.
If finalized, this would end large-scale compounding of these weight-loss drugs by 503B outsourcing facilities, even in future shortages. The 503B pathway is different from the 503A pathway being discussed for peptides like BPC-157 — 503B covers large-scale outsourcing facilities, while 503A covers individual patient-specific compounding. For a full breakdown, see our guide to 503A vs 503B pharmacies.
This matters because many of the telehealth companies that built businesses around compounded semaglutide and tirzepatide are now pivoting toward non-GLP-1 peptides. The PCAC recommendations for BPC-157, MOTS-c, and others have taken on additional commercial significance against that backdrop.
What This Means for Patients and Consumers
If you’re following this because you’re interested in accessing one of these peptides, here’s the practical summary:
Right now: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax are all in Category 1 under the FDA’s enforcement framework. Some providers are prescribing them through licensed 503A compounding pharmacies. This is a real pathway, but it carries more regulatory ambiguity than a formal listing would. Getting started requires a prescribing provider, appropriate bloodwork, and a licensed pharmacy.
In the coming months: Watch for the NPRM. When the FDA publishes its proposed rule, that will be the first concrete signal of whether the agency intends to follow the committee’s recommendation. The public comment period that follows will be the last opportunity for stakeholders to weigh in.
By late 2027: If rulemaking proceeds on schedule and the FDA follows the advisory vote, these six peptides should have a formal legal compounding pathway via the 503A Bulks List. That would shift the market substantially — from a gray-market and enforcement-discretion model to a codified, physician-supervised, pharmacy-dispensed system.
None of this makes these substances FDA-approved drugs. It does not mean they will be covered by insurance. It means licensed pharmacies would be explicitly authorized to prepare them for patients with valid prescriptions.
Frequently Asked Questions
Sources and Further Reading
This article draws on the FDA’s official PCAC meeting page (docket FDA-2025-N-6895), the FDA briefing document published July 2026, vote tallies reported by AJMC, McDermott Will & Emery, PharmExec, NCPA, and Affinity Whole Health. All vote counts were cross-referenced across multiple sources reporting from the White Oak Campus proceedings.
For the regulatory framework: 21 C.F.R. § 216.23 (503A Bulks List); Section 503A, Federal Food, Drug, and Cosmetic Act; FDA interim enforcement categories guidance document.